A 10-year follow-up of the European multicenter trial of interferon {beta}-1b in secondary-progressive multiple sclerosis

Conclusions:
The results from this analysis did not provide convincing evidence to support a favorable long-term outcome in those patients allocated IFNB-1b during the RCT, in our SPMS cohort. The progressive stage of the disease remains largely unpredictable by clinical and conventional MRI measures, so better prognostic markers are needed.

Source: Multiple Sclerosis - March 17, 2016 Category: Neurology Authors: Kuhle, J., Hardmeier, M., Disanto, G., Gugleta, K., Ecsedi, M., Lienert, C., Amato, M., Baum, K., Buttmann, M., Bayas, A., Brassat, D., Brochet, B., Confavreux, C., Edan, G., Färkkilä, M., Fredrikson, S., Frontoni, M., DHooghe, M., Hutchin Tags: Original Research Papers Source Type: research